VIGIL NEUROSCIENCE INC (VIGL)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)

/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The...

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to...

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to...

Vigil Neuroscience to Present at Upcoming September Investor Conferences

Vigil Neuroscience to Present at Upcoming September Investor Conferences

WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)

/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The...

VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vigil Neuroscience (NASDAQ:VIGL) just reported results for the second quarter o...

VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q2 2024

VIGL stock results show that Vigil Neuroscience beat analyst estimates for earnings per share the second quarter of 2024.

Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

- Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy...

Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics

Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)

Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)

- First presentation of clinical data on sTREM2 from SAD cohorts in ongoing Phase 1 clinical trial of VG-3927 in healthy volunteers demonstrate...

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease

- Safety, tolerability, pharmacokinetic and pharmacodynamic profile of VG-3927 supports continued development as potential once-daily oral therapy for...

Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference

Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference

WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to...

Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)

/PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The...

Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today?

Tonix Pharmaceuticals stock is falling on Thursday after the company announced a proposed public offering for shares of TNXP.

Why Is Branchout Food (BOF) Stock Down 39% Today?

Branchout Food stock is down on Thursday after the company priced an offering of 1.75 million shares of BOF at 80 cents each.

Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?

Vigil Neuroscience stock is up with heavy trading of VIGL shares this morning on news of a $40 million investment from Sanofi.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning!

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation...

3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition

Penny stocks are risky because of their insane volatility — but these have a chance to 10x your investments.

3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition

Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year.

Vigil Neuroscience to Present in Upcoming June Investor Conferences

Vigil Neuroscience to Present in Upcoming June Investor Conferences

WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to...

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T.

VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024

VIGL stock results show that Vigil Neuroscience beat analyst estimates for earnings per share the first quarter of 2024.

VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vigil Neuroscience (NASDAQ:VIGL) just reported results for the first quarter of...

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial...